The invention features adhesive devices for holding objects (e.g., bone fragments) fixed with respect to each other.

The invention relates to products in the form of pads or films for treating bleeding wounds, said products being formed from an organic polymer material that contains at least one particulate, crystalline inorganic polyphosphate finely divided in the organic polymer material, and the polyphosphate having a solubility in deionized water at 20° C. of less than 5 g/L, particularly less than 1 g/L, and the anion of the polyphosphate on average (number average) having at least four phosphorus atoms per polyphosphate anion.

The invention relates to products in the form of pads or films for treating bleeding wounds, said products being formed from an organic polymer material that contains at least one particulate, crystalline inorganic polyphosphate finely divided in the organic polymer material, and the polyphosphate having a solubility in deionized water at 20° C. of less than 5 g/L, particularly less than 1 g/L, and the anion of the polyphosphate on average (number average) having at least four phosphorus atoms per polyphosphate anion.

Certain small molecule amino acid phosphate compounds such as phosphoserine and certain multivalent metal compounds such as calcium phosphate containing cements have been found to have improved properties and form an interpenetrating network in the presence of a polymer that contains either an electronegative carbonyl oxygen atom of the ester group or an electronegative nitrogen atom of the amine group as the bonding sites of the polymer surfaces to the available multivalent metal ions.

The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.

The present disclosure relates to methods and compositions for the treatment of degenerate bone in a patient. In some embodiments, the methods and compositions disclosed herein are useful in the treatment, prevention, or in delaying the progression of a bone disease linked to bone degeneration, such as osteoarthritis (“OA”), rheumatoid arthritis, and avascular necrosis.

A bone material composite granule, a manufacturing method and usage method thereof, and a bone cement constructed using the composite granule. The bone material composite granule comprises a co-polymer of a hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA) and a calcium phosphate coated on the surface of the co-polymer. A synthesized bone replacement material has improved biocompatibility, bone conduction, and rheological characteristics, and enhanced mechanics and mechanical performance. The bone material can be used in the fields of osteonecrosis, osteoporosis, osteoarthritis, vertebroplasty, bone fracture, bone cyst, alveolar atrophy, subchondral bone defect, subchondral bone cyst, maxillofacial surgery, plastic surgery, minimally invasive procedure, and the like.

A bone material composite granule, a manufacturing method and usage method thereof, and a bone cement constructed using the composite granule. The bone material composite granule comprises a co-polymer of a hydroxyethyl methacrylate (HEMA) and methyl methacrylate (MMA) and a calcium phosphate coated on the surface of the co-polymer. A synthesized bone replacement material has improved biocompatibility, bone conduction, and rheological characteristics, and enhanced mechanics and mechanical performance. The bone material can be used in the fields of osteonecrosis, osteoporosis, osteoarthritis, vertebroplasty, bone fracture, bone cyst, alveolar atrophy, subchondral bone defect, subchondral bone cyst, maxillofacial surgery, plastic surgery, minimally invasive procedure, and the like.

A method for controlling generation of biologically desirable voids in a composition placed in proximity to bone or other tissue in a patient by selecting at least one water-soluble inorganic material having a desired particle size and solubility, and mixing the water-soluble inorganic material with at least one poorly-water-soluble or biodegradable matrix material. The matrix material, after it is mixed with the water-soluble inorganic material, is placed into the patient in proximity to tissue so that the water-soluble inorganic material dissolves at a predetermined rate to generate biologically desirable voids in the matrix material into which bone or other tissue can then grow.

A three-dimensional, biocompatible scaffold precursor composition for room-temperature printing a bio-compatible polymer/hydroxyapatite composite scaffold includes a room-temperature slurry, comprising a mixture of a sold phase that includes a mixture of tetracalcium phosphate (TTCP; Ca.sub.4(PO.sub.4).sub.2O) and dicalcium phosphate anhydrous (DCPA; CaHPO.sub.4), and a liquid phase that includes a polymer in a solvent. The solvent may be Ethanol (EtOH) or Tetrahydrofuran (THF), and the polymer may be polyvinyl butyral (PVB), polycaprolactone (PCL), or poly lactic-co-glycolic acid (PLGA). The slurry is printed at room temperature in aqueous phosphate (NaH.sub.2PO.sub.4) bath, which works as hardening accelerator, forming the polymer/hydroxyapatite composite scaffold